Project Grant R01DK140040
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $974,604 Project Grant to Zvelt Therapeutics Inc. on September 9, 2025. The funding supports the development of a novel gene therapy for the treatment of lipodystrophy, a rare and often underdiagnosed condition characterized by abnormal or degenerative adipose tissue. The therapy utilizes recombinant adeno-associated...
- This federal Project Grant award of $544,963, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the protein frataxin (FXN) in metabolic dysfunction-associated steatotic liver disease (MASLD). The research conducted under this award will examine whether FXN deficiency induces and whether restoration of FXN expression prevents...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, awarded a $728,801 Project Grant to the Regents of the University of Michigan under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant funds a 5-year project to test a novel weight navigation program aimed at overcoming barriers to obesity treatment in primary care settings. The project seeks to improve utilization of effective...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $776,863 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Regents of the University of Michigan. The award will fund a multi-ancestry whole genome sequencing analysis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a globally prevalent condition caused by excess fat accumulation in the liver. The research aims to uncover...
- This federal Project Grant award of $803,748 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant is funding research to investigate the modulation of insulin signaling in adipocytes (fat cells) and how improved adipocyte insulin sensitivity can contribute to positive metabolic outcomes. The research team at The University of Texas Southwestern Medical...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $719,250 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Biotherapeutics, Inc., a clinical-stage biotech company in Virginia. The grant supports the development of novel, oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes (T2D). The specific aims are to: 1) Evaluate the therapeutic efficacy of the lead drug candidate...
- This $2,060,811 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research on the role of activin type II receptor signaling in muscle hypertrophy, obesity, and weight loss. The research aims to understand how blocking the activin type II receptor can preserve lean muscle mass while maximizing fat loss during obesity treatment,...
- This Project Grant award, totaling $502,233, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research conducted by the Regents of the University of Michigan to investigate neuron populations in the nucleus of the solitary tract (NTS) that mediate the aversive and non-aversive suppression of food intake. The research aims to further...
- This $2,971,227 federal Project Grant, awarded on September 4, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to investigate the role of fatty acids in regulating cellular metabolism and protein synthesis in the context of fasting, inflammation, and metabolic diseases. The research aims to uncover novel signaling pathways through which fatty...
- This $128,286 Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research into the mechanisms of renal lipotoxicity and its contribution to the development of chronic kidney disease (CKD). The principal investigator will investigate the protective role of the FAF2 gene knockout in mitigating palmitate-induced lipotoxicity in...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to test the effectiveness of tirzepatide for treating familial partial lipodystrophy (FPLD). FPLD is a rare metabolic disorder characterized by loss of fat tissue in the limbs and trunk, leading to metabolic and endocrine complications. The $793,098 award to the Regents of the University of Michigan will fund a research project from September 2025 through June 2030 to assess whether tirzepatide, a dual incretin receptor agonist that induces significant weight loss, can provide clinical benefit to FPLD patients by decreasing their excessive caloric intake. This project seeks to address the unmet medical need for FPLD, as there is currently no FDA-approved therapy for this condition in the United States.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $793.1k | 9/3/25 |